RAPT THERAPEUTICS INC (RAPT) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:RAPT • US75382E2081

57.69 USD
+0.01 (+0.02%)
At close: Feb 6, 2026
57.65 USD
-0.04 (-0.07%)
After Hours: 2/6/2026, 8:02:23 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

3

RAPT gets a fundamental rating of 3 out of 10. The analysis compared the fundamentals against 525 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for RAPT as it has an excellent financial health rating, but there are worries on the profitability. RAPT has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

1

1. Profitability

1.1 Basic Checks

  • In the past year RAPT has reported negative net income.
  • RAPT had a negative operating cash flow in the past year.
  • RAPT had negative earnings in each of the past 5 years.
  • RAPT had a negative operating cash flow in each of the past 5 years.
RAPT Yearly Net Income VS EBIT VS OCF VS FCFRAPT Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

  • RAPT has a Return On Assets of -63.74%. This is comparable to the rest of the industry: RAPT outperforms 40.38% of its industry peers.
  • With a Return On Equity value of -69.51%, RAPT perfoms like the industry average, outperforming 57.14% of the companies in the same industry.
Industry RankSector Rank
ROA -63.74%
ROE -69.51%
ROIC N/A
ROA(3y)-50.99%
ROA(5y)-46.45%
ROE(3y)-60.69%
ROE(5y)-53.99%
ROIC(3y)N/A
ROIC(5y)N/A
RAPT Yearly ROA, ROE, ROICRAPT Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60

1.3 Margins

  • RAPT does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RAPT Yearly Profit, Operating, Gross MarginsRAPT Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K -5K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. Health

2.1 Basic Checks

  • RAPT has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for RAPT has been increased compared to 5 years ago.
  • RAPT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RAPT Yearly Shares OutstandingRAPT Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M
RAPT Yearly Total Debt VS Total AssetsRAPT Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

  • An Altman-Z score of 62.89 indicates that RAPT is not in any danger for bankruptcy at the moment.
  • RAPT has a better Altman-Z score (62.89) than 97.52% of its industry peers.
  • RAPT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 62.89
ROIC/WACCN/A
WACCN/A
RAPT Yearly LT Debt VS Equity VS FCFRAPT Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

  • A Current Ratio of 12.04 indicates that RAPT has no problem at all paying its short term obligations.
  • RAPT has a Current ratio of 12.04. This is amongst the best in the industry. RAPT outperforms 86.86% of its industry peers.
  • A Quick Ratio of 12.04 indicates that RAPT has no problem at all paying its short term obligations.
  • With an excellent Quick ratio value of 12.04, RAPT belongs to the best of the industry, outperforming 86.86% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 12.04
Quick Ratio 12.04
RAPT Yearly Current Assets VS Current LiabilitesRAPT Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. Growth

3.1 Past

  • RAPT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 50.09%, which is quite impressive.
EPS 1Y (TTM)50.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.71%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • Based on estimates for the next years, RAPT will show a quite strong growth in Earnings Per Share. The EPS will grow by 10.66% on average per year.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y89.38%
EPS Next 2Y36.64%
EPS Next 3Y22.49%
EPS Next 5Y10.66%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
RAPT Yearly Revenue VS EstimatesRAPT Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2030 2031 2032 2033 200M 400M 600M 800M 1B
RAPT Yearly EPS VS EstimatesRAPT Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 -5 -10 -15 -20 -25

More info and screens

Find the best growth stocksShow best growing peers

1

4. Valuation

4.1 Price/Earnings Ratio

  • RAPT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Also next year RAPT is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RAPT Price Earnings VS Forward Price EarningsRAPT Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RAPT Per share dataRAPT EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 -5 -10

4.3 Compensation for Growth

  • A more expensive valuation may be justified as RAPT's earnings are expected to grow with 22.49% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y36.64%
EPS Next 3Y22.49%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • RAPT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RAPT THERAPEUTICS INC

NASDAQ:RAPT (2/6/2026, 8:02:23 PM)

After market: 57.65 -0.04 (-0.07%)

57.69

+0.01 (+0.02%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-06
Earnings (Next)03-04
Inst Owners55.16%
Inst Owner Change2.61%
Ins Owners0.24%
Ins Owner Change0%
Market Cap1.60B
Revenue(TTM)N/A
Net Income(TTM)-105.64M
Analysts81.18
Price Target54.97 (-4.71%)
Short Float %7.17%
Short Ratio1.25
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)16.19%
Min EPS beat(2)0.82%
Max EPS beat(2)31.56%
EPS beat(4)3
Avg EPS beat(4)-31.54%
Min EPS beat(4)-200.44%
Max EPS beat(4)41.9%
EPS beat(8)7
Avg EPS beat(8)-11.46%
EPS beat(12)9
Avg EPS beat(12)-7.23%
EPS beat(16)13
Avg EPS beat(16)-3.16%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-7.44%
PT rev (3m)-3.77%
EPS NQ rev (1m)-3.34%
EPS NQ rev (3m)11.7%
EPS NY rev (1m)-1.23%
EPS NY rev (3m)13.56%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 10.52
P/tB 10.52
EV/EBITDA N/A
EPS(TTM)-11.06
EYN/A
EPS(NY)-3.31
Fwd EYN/A
FCF(TTM)-3.13
FCFYN/A
OCF(TTM)-3.12
OCFYN/A
SpS0
BVpS5.48
TBVpS5.48
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -63.74%
ROE -69.51%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-50.99%
ROA(5y)-46.45%
ROE(3y)-60.69%
ROE(5y)-53.99%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score6
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 8.64%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.04
Quick Ratio 12.04
Altman-Z 62.89
F-Score6
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)61.2%
Cap/Depr(5y)59.06%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)50.09%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%82.71%
EPS Next Y89.38%
EPS Next 2Y36.64%
EPS Next 3Y22.49%
EPS Next 5Y10.66%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y2.06%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year26.65%
EBIT Next 3Y-4.65%
EBIT Next 5YN/A
FCF growth 1Y7.06%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y6.03%
OCF growth 3YN/A
OCF growth 5YN/A

RAPT THERAPEUTICS INC / RAPT FAQ

Can you provide the ChartMill fundamental rating for RAPT THERAPEUTICS INC?

ChartMill assigns a fundamental rating of 3 / 10 to RAPT.


Can you provide the valuation status for RAPT THERAPEUTICS INC?

ChartMill assigns a valuation rating of 1 / 10 to RAPT THERAPEUTICS INC (RAPT). This can be considered as Overvalued.


Can you provide the profitability details for RAPT THERAPEUTICS INC?

RAPT THERAPEUTICS INC (RAPT) has a profitability rating of 1 / 10.


What is the financial health of RAPT THERAPEUTICS INC (RAPT) stock?

The financial health rating of RAPT THERAPEUTICS INC (RAPT) is 8 / 10.